Citius Pharma Files 8-K on Shareholder Votes
Ticker: CTXR · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1506251
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Citius Pharma filed an 8-K for shareholder votes. Governance update.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on March 10, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its incorporation in Nevada and its principal executive offices located at 11 Commerce Drive, 1st Floor, Cranford, NJ.
Why It Matters
This filing is important for investors to understand the governance and voting matters affecting Citius Pharmaceuticals, Inc. It provides transparency on key decisions being made by the company's security holders.
Risk Assessment
Risk Level: low — This filing is primarily procedural, reporting on shareholder votes and corporate information, and does not contain significant new financial or operational risks.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
- March 10, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Citius Pharmaceuticals, Inc.?
The primary purpose is to report on matters submitted to a vote of security holders, as indicated by the 'Submission of Matters to a Vote of Security Holders' item information.
When was this 8-K filing submitted?
The filing was submitted on March 10, 2025.
In which state is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the address of Citius Pharmaceuticals, Inc.'s principal executive offices?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number for Citius Pharmaceuticals, Inc. is 001-38174.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding Citius Pharmaceuticals, Inc. (CTXR).